
Becton, Dickinson and Co.
BDXBecton, Dickinson and Co. (BDX) is a global medical technology company specializing in the development and manufacturing of medical devices, supplies, and laboratory equipment. Founded in 1897, it is known for its innovations in healthcare including syringes, safety-engineered devices, and diagnostic products, serving healthcare institutions, life sciences, and general medical markets worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 31, 2025 | $1.05 | 2025-12-08 | 2025-12-08 |
| September 30, 2025 | $1.04 | 2025-09-08 | 2025-09-08 |
| June 30, 2025 | $1.04 | 2025-06-09 | 2025-06-09 |
| March 31, 2025 | $1.04 | 2025-03-10 | 2025-03-10 |
| December 31, 2024 | $1.04 | 2024-12-09 | 2024-12-09 |
Dividends Summary
- Consistent Payer: Becton, Dickinson and Co. has rewarded shareholders with 89 dividend payments over the past 21 years.
- Total Returned Value: Investors who held BDX shares during this period received a total of $51.35 per share in dividend income.
- Latest Payout: The most recent dividend of $1.05/share was paid 23 days ago, on December 31, 2025.
- Yield & Schedule: BDX currently pays dividends quarterly with an annual yield of 2.02%.
- Dividend Growth: Since 2004, the dividend payout has grown by 600.0%, from $0.15 to $1.05.
- Dividend Reliability: BDX has maintained or increased its dividend for 89 consecutive payments.
Company News
The global anatomic pathology market is projected to grow from $93.03 billion in 2024 to $224.44 billion by 2033 at a CAGR of 10.28%, driven by rising cancer burden, aging populations, and AI-powered digital pathology adoption. North America leads with over 41% market share, supported by advanced healthcare infrastructure and precision oncology i...
A comprehensive market analysis report on atherectomy devices covering 39 countries with forecasts through 2036. The market is driven by the shift toward minimally-invasive techniques for treating coronary and peripheral artery diseases, replacing traditional bypass surgery. The report provides detailed market segmentation, intervention volumes, ...
Becton, Dickinson and Company received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, with market launch expected in early 2026. The advanced system features high and low vacuum strengths, 360-degree sampling ability, and multiple probe options. However, analysts expect slightly lower earnings and revenue co...
The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North Ame...
William Blair initiated Outperform coverage on Waters Corporation following its merger with Becton Dickinson's Biosciences & Diagnostic Solutions business. The analyst sees greater synergy upside than initially priced in, with EPS accretion of ~$0.10 in 2026 rising to ~$2.70 by 2028. William Blair projects roughly 20% upside by year-end 2026 and ...







